Lipid nanoparticles are widely adopted vehicles for oligonucleotide-based therapeutics and vaccines.
Watch Now
Pharmtech
Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes. Often, patient factors and insights are not considered or discovered until the later phases of drug development when dose form, dose strength, and route of administration are already decided. There is tremendous potential benefit of equipping formulators and other scientists with patient insights earlier in the development process so that the drug product can be designed to address the specific needs of target patient populations.
Watch Now
Pharmaceutical manufacturers are facing unprecedented challenges from supply chain disruptions, significant demand fluctuations, reliability.
Watch Now
pharmexec
We are entering a new era in which real-world evidence is transforming how drugs are developed, approved, and commercialized. As FDA leads the change with a 3-year strategy—the Framework for FDA’s Real-World Evidence Program—the industry is launched on a shared learning process to understand where and when RWE can support regulatory decision-making. This webcast brings together industry experts in research and pharma to explore how forward-thinking pharmaceutical organizations are adopting new approaches for the use of RWE in drug development and approval.
Watch Now